Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials.
Mark G LebwohlAhmed M SolimanHongbo YangJessie WangKaitlin HaganByron PadillaAndreas PinterPublished in: Dermatology and therapy (2021)
ClinicalTrials.gov identifiers: UltIMMa-1 (NCT02684370), NCT02684357 (UltIMMa-2), IMMvent (NCT02694523), IMMhance (NCT02672852).
Keyphrases